UA99555C2 - Melanocortin receptor agonists - Google Patents

Melanocortin receptor agonists

Info

Publication number
UA99555C2
UA99555C2 UAA201105960A UAA201105960A UA99555C2 UA 99555 C2 UA99555 C2 UA 99555C2 UA A201105960 A UAA201105960 A UA A201105960A UA A201105960 A UAA201105960 A UA A201105960A UA 99555 C2 UA99555 C2 UA 99555C2
Authority
UA
Ukraine
Prior art keywords
melanocortin receptor
receptor agonists
agonistic
isomer
melanocortin
Prior art date
Application number
UAA201105960A
Other languages
English (en)
Ukrainian (uk)
Inventor
Коо Ли
Санг Дае Ли
Санг Пил Моон
Ин Ае Ахн
Сунг Пил Чой
Хьюн Хо Ли
Донг Сап Шим
Соо Йонг Чанг
Хьюн Мин Ли
Original Assignee
Элджи Лайф Саенсез Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Элджи Лайф Саенсез Лтд. filed Critical Элджи Лайф Саенсез Лтд.
Publication of UA99555C2 publication Critical patent/UA99555C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Данное изобретение касается соединения с высокой агонистической активностью к рецептору меланокортина или его фармацевтически приемлемой соли или изомера, а также агонистической к рецептору меланокортина композиции, которая содержит указанное соединение или его фармацевтически приемлемую соль или изомер как активный ингредиент.
UAA201105960A 2008-11-12 2009-10-11 Melanocortin receptor agonists UA99555C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20080112403 2008-11-12

Publications (1)

Publication Number Publication Date
UA99555C2 true UA99555C2 (en) 2012-08-27

Family

ID=42165801

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201105960A UA99555C2 (en) 2008-11-12 2009-10-11 Melanocortin receptor agonists

Country Status (26)

Country Link
US (4) US8288386B2 (ru)
EP (1) EP2350060B1 (ru)
JP (1) JP5399506B2 (ru)
KR (1) KR101141976B1 (ru)
CN (1) CN102282141B (ru)
AR (1) AR074109A1 (ru)
AU (1) AU2009314827B2 (ru)
BR (1) BRPI0921063B8 (ru)
CA (1) CA2742248C (ru)
CL (1) CL2011001073A1 (ru)
CO (1) CO6362006A2 (ru)
CR (1) CR20110250A (ru)
EA (1) EA019146B1 (ru)
EC (1) ECSP11011026A (ru)
GE (1) GEP20135850B (ru)
IL (1) IL212468A0 (ru)
MA (1) MA32774B1 (ru)
MX (1) MX2011004583A (ru)
NZ (1) NZ592512A (ru)
PE (1) PE20110684A1 (ru)
TN (1) TN2011000222A1 (ru)
TW (1) TWI389903B (ru)
UA (1) UA99555C2 (ru)
UY (1) UY32238A (ru)
WO (1) WO2010056022A2 (ru)
ZA (1) ZA201103154B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
US9018395B2 (en) 2011-01-27 2015-04-28 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
RS62701B1 (sr) 2011-12-29 2022-01-31 Rhythm Pharmaceuticals Inc Postupak lečenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
CN104203915B (zh) 2012-04-25 2017-03-08 霍夫曼-拉罗奇有限公司 (3，4‑二氯‑苯基)‑((s)‑3‑丙基‑吡咯烷‑3‑基)‑甲酮盐酸盐和制造方法
CN103420981A (zh) * 2012-05-21 2013-12-04 中国医学科学院药物研究所 含有取代吡咯烷基的硫代吗啉类化合物
CN108601816A (zh) 2015-09-30 2018-09-28 节奏制药公司 治疗黑皮质素-4受体路径相关联病症的方法
US20210169969A1 (en) 2018-04-06 2021-06-10 Leonardus H.T. Van Der Ploeg Compositions for treating kidney disease
PT3953327T (pt) * 2019-11-07 2024-02-05 Lg Chemical Ltd Agonistas do recetor de melanocortina-4
JP2023548327A (ja) 2020-10-29 2023-11-16 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法
JP2023548162A (ja) 2020-10-29 2023-11-15 エルジー・ケム・リミテッド 無定形のメラノコルチン－４受容体アゴニスト
JP2023548163A (ja) 2020-10-29 2023-11-15 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉｉおよびその製造方法
TWI823169B (zh) 2020-10-29 2023-11-21 南韓商Ｌｇ化學股份有限公司 黑皮質素受體促效劑化合物的晶形ⅲ及其製備方法
MX2023004731A (es) 2020-10-29 2023-05-10 Lg Chemical Ltd Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma.
CN116782877A (zh) * 2020-12-22 2023-09-19 株式会社Lg化学 作为黑皮质素-4受体的选择性激动剂的用途
CN116635033A (zh) 2020-12-22 2023-08-22 株式会社Lg化学 黑皮质素受体激动剂化合物的结晶形式iii及其制备方法
EP4249483A4 (en) * 2020-12-22 2024-05-15 Lg Chemical Ltd CRYSTALLINE FORM I OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR THE PREPARATION THEREOF
JP2024501828A (ja) 2020-12-22 2024-01-16 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の結晶形ｉｉおよびその製造方法
JP2024500906A (ja) 2020-12-22 2024-01-10 エルジー・ケム・リミテッド 無定形のメラノコルチン受容体アゴニストおよびその製造方法
AU2022209657A1 (en) * 2021-01-21 2023-07-20 Lg Chem, Ltd. Uses of melanocortin-4 receptor agonist
JP2024508469A (ja) 2021-02-26 2024-02-27 エルジー・ケム・リミテッド メラノコルチン－４受容体アゴニスト
EP4317149A1 (en) 2021-05-06 2024-02-07 Lg Chem, Ltd. Crystalline form v of melanocortin receptor agonist compound, and method for preparing same
AU2022269993A1 (en) 2021-05-06 2023-11-02 Lg Chem, Ltd. Crystal form vii of melanocortin receptor agonist compound and method for preparing same
BR112023022432A2 (pt) 2021-05-07 2024-01-09 Lg Chemical Ltd Formas cristalinas iv de sais de ácidos orgânicos de composto agonista do receptor de melanocortina, seus metódos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas
EP4321512A1 (en) 2021-05-07 2024-02-14 Lg Chem, Ltd. Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same
BR112023022334A2 (pt) 2021-05-07 2023-12-26 Lg Chemical Ltd Formas cristalinas de sulfato do composto agonista do receptor de melanocortina, seus métodos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
AU4929601A (en) 2000-03-23 2001-10-03 Merck & Co Inc Substituted piperidines as melanocortin receptor agonists
AU4928101A (en) 2000-03-23 2001-10-03 Merck & Co Inc Spiropiperidine derivatives as melanocortin receptor agonists
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
CA2419310A1 (en) 2000-08-23 2002-02-28 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
US7157463B2 (en) 2001-01-23 2007-01-02 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
JP2004524297A (ja) 2001-01-23 2004-08-12 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニスト
ES2247298T3 (es) 2001-01-23 2006-03-01 Eli Lilly And Company Derivados de piperazina y piperidina como agonistas del receptor de melanocortina.
EP1372653B1 (en) 2001-02-28 2006-10-04 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
ATE430565T1 (de) 2001-02-28 2009-05-15 Merck & Co Inc Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten
EP1383501B1 (en) 2001-02-28 2007-04-04 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
EP1385823B1 (en) 2001-04-09 2006-12-13 Chiron Corporation Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
WO2004078717A1 (en) 2003-03-03 2004-09-16 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
WO2004087159A1 (en) 2003-03-26 2004-10-14 Merck & Co., Inc. Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
WO2005047251A1 (en) 2003-11-12 2005-05-26 Lg Life Sciences Ltd. Melanocortin receptor agonists
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
CA2573714A1 (en) 2004-07-16 2006-02-23 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
EP1773338B1 (en) 2004-07-19 2010-01-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1928460A2 (en) 2005-08-01 2008-06-11 Pfizer Limited Mc4r-agonists for the treatment of urinary tract dysfunction
CA2617654A1 (en) 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CA2624031A1 (en) 2005-09-30 2007-04-12 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
AU2006304305B2 (en) 2005-10-18 2010-04-01 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2007131570A (ja) 2005-11-09 2007-05-31 Mitsubishi Pharma Corp 新規なアミノピロリジン誘導体
US8138188B2 (en) 2006-02-23 2012-03-20 Pfizer Inc. Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
WO2007096186A1 (en) 2006-02-23 2007-08-30 Santhera Pharmaceuticals (Schweiz) Ag Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators
ATE508111T1 (de) 2006-06-09 2011-05-15 Action Pharma As Phenylpyrrolaminoguanidinderivate
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
US20090253744A1 (en) 2006-09-27 2009-10-08 Bakshi Raman K Acylated piperidine derivatives as melanocortin-4 receptor modulators
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists

Also Published As

Publication number Publication date
US20110224219A1 (en) 2011-09-15
US8288386B2 (en) 2012-10-16
US8039622B2 (en) 2011-10-18
JP5399506B2 (ja) 2014-01-29
US8183243B2 (en) 2012-05-22
ECSP11011026A (es) 2011-06-30
BRPI0921063B1 (pt) 2021-03-16
US20110237795A1 (en) 2011-09-29
CN102282141B (zh) 2014-09-10
UY32238A (es) 2010-01-05
JP2012508730A (ja) 2012-04-12
PE20110684A1 (es) 2011-09-28
US20100120783A1 (en) 2010-05-13
WO2010056022A3 (en) 2010-09-10
CN102282141A (zh) 2011-12-14
EP2350060A2 (en) 2011-08-03
BRPI0921063B8 (pt) 2021-05-25
CL2011001073A1 (es) 2011-10-07
US8236955B2 (en) 2012-08-07
TN2011000222A1 (en) 2012-12-17
CO6362006A2 (es) 2012-01-20
AU2009314827B2 (en) 2012-04-05
AU2009314827A1 (en) 2010-05-20
EA201170676A1 (ru) 2011-12-30
GEP20135850B (en) 2013-06-10
CR20110250A (es) 2011-08-26
KR101141976B1 (ko) 2012-05-07
BRPI0921063A2 (pt) 2015-08-25
CA2742248A1 (en) 2010-05-20
KR20100053458A (ko) 2010-05-20
AR074109A1 (es) 2010-12-22
EP2350060A4 (en) 2012-07-25
TWI389903B (zh) 2013-03-21
MA32774B1 (fr) 2011-11-01
IL212468A0 (en) 2011-06-30
EP2350060B1 (en) 2013-09-18
WO2010056022A2 (en) 2010-05-20
EA019146B1 (ru) 2014-01-30
US20110245500A1 (en) 2011-10-06
ZA201103154B (en) 2012-01-25
CA2742248C (en) 2014-01-14
NZ592512A (en) 2012-12-21
MX2011004583A (es) 2011-06-01
TW201022246A (en) 2010-06-16

Similar Documents

Publication Publication Date Title
TN2011000222A1 (en) Melanocortin receptor agonists
WO2007098474A8 (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
IN2012DN01241A (ru)
WO2009098230A3 (en) Pesticidal mixtures
MX2013001493A (es) Composiciones orales que comprenden un compuesto de cinc y un agente anti-microbiano.
SG195375A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MY154909A (en) Novel thiophene derivatives
MY149869A (en) Thiophene derivatives as s1p1/edg1 receptor agonists
IL192948A0 (en) Novel pyridine derivatives
HK1132175A1 (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
MX2010007807A (es) Mezclas de plaguicidas.
TW200942524A (en) Novel aminomethyl benzene derivatives
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
MY178894A (en) Therapeutic compositions containing macitentan
MX2010008177A (es) Mezclas de plaguicidas.
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
TW200942530A (en) Pyridine compounds
EA201071395A1 (ru) Ингибитор толерантности к анальгетику
MX2011008756A (es) Composicion insecticida que comprende un derivado de hidracida antranilica y un neonicotinoide.
WO2012030957A3 (en) Non-hygroscopic salts of 5-ht2c agonists
WO2012128582A3 (en) A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
WO2009098228A3 (en) Pesticidal mixtures
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
MY160825A (en) Lanthionine derivatives
MX2009012761A (es) Neramexano para el tratamiento de nistagmo.